Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580015 | 1.00 | PTGER1 (0.41) | PTGER1ALDH1A1KDM4EKMT2AMDM2 | |
| SCHEMBL20213900 | 0.92 | PTGER1 (0.39) | PTGER1ALDH1A1KDM4EKMT2AMDM2 | |
| SCHEMBL29579457 | 0.92 | PTGER1 (0.39) | PTGER1ALDH1A1KDM4EKMT2AMDM2 | |
| SCHEMBL20214530 | 0.89 | PTGER1 (0.44) | PTGER1ALDH1A1KDM4EKMT2AMDM2 | |
| SCHEMBL20214550 | 0.89 | PTGER1 (0.43) | PTGER1ALDH1A1KDM4EKMT2AMDM2 | |
| SCHEMBL20214265 | 0.89 | PTGER1 (0.43) | PTGER1ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL29579307 | 0.89 | PTGER1 (0.43) | PTGER1ALDH1A1KDM4EKMT2AMDM2 | |
| SCHEMBL20213956 | 0.87 | ALDH1A1 (0.44) | PTGER1ALDH1A1KDM4EKMT2AMDM2 | |
| SCHEMBL18295215 | 0.87 | NTRK1 (0.40) | PTGER1ALDH1A1KDM4EKMT2AMDM2 | |
| SCHEMBL29579461 | 0.87 | ALDH1A1 (0.44) | PTGER1ALDH1A1KDM4EKMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230076820-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2023-03-09 | — | — | US | claimed |
| CN-110603254-A | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2019-12-20 | — | — | CN | claimed |
| US-20190345152-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2019-11-14 | — | — | US | claimed |
| CN-110603254-B | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230076820-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2023-03-09 | — | — | US | disclosed |
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-11192887-B2 | — | — | 2021-12-07 | — | — | US | disclosed |
| US-11192887-B2 | — | — | 2021-12-07 | — | — | US | disclosed |
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | BANTAM PHARMACEUTICAL LLC (US) | 2021-09-09 | — | — | US | disclosed |
| CN-112770813-A | Methods of treating cancer with substituted pyrrole and pyrazole compounds and diagnosing cancer sensitive to treatment with substituted pyrrole and pyrazole compounds | 班塔姆制药有限责任公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-110603254-A | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2019-12-20 | — | — | CN | disclosed |
| US-20190345152-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2019-11-14 | — | — | US | disclosed |
| US-20190345152-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2019-11-14 | — | — | US | disclosed |
| EP-3548482-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AND METHODS OF USING THEM FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bantam Pharmaceutical, LLC (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018102453-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AND METHODS OF USING THEM FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | BANTAM PHARMACEUTICAL, LLC (US) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | KRAS, TP53, CCNI | PTGER1 614/4885ALDH1A1 355/4885KDM4E 3557/4885 |
| US-20190345152-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | KRAS, TP53, CCNI | PTGER1 614/4885ALDH1A1 355/4885KDM4E 3557/4885 |
| US-11192887-B2 | — | KRAS, TP53, CCNE1 | PTGER1 1070/4885ALDH1A1 207/4885KDM4E 3282/4885 |
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | TP53, MKI67, VHL | PTGER1 980/4885ALDH1A1 335/4885KDM4E 2356/4885 |
| US-20230076820-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | KRAS, TP53, NRAS | PTGER1 530/4885ALDH1A1 519/4885KDM4E 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.